Sam Brusco, Associate Editor02.27.23
Clarapath, a robotics company aiming to change how pathology labs process human and animal tissue, has acquired Mountain View, Calif.-based Crosscope.
Crosscope is a digital pathology firm that has a turnkey imaging solution with workflow tools, slide management, and artificial intelligence (AI) and machine learning (ML) tech to help pathologists make quicker, more informed decisions.
The acquisition combines Clarapath’s SectionStar, a fully automated, all-in-one tissue sectioning and transfer system with Crosscope’s workflow and computational pathology tools. The combined technologies aim to enable faster, more cost effective, and higher quality care delivery.
"Clarapath is thrilled to welcome Crosscope to the Clarapath team. We believe that the combination of SectionStar's exceptional automated robotics with Crosscope's advanced workflow and computational pathology tools provide an end-to-end platform for more patient-centric care in human and animal health," Eric Feinstein, CEO of Clarapath told the press. "Our combined offering will solve some of the most pressing issues in the lab such as labor shortages, quality control challenges, and the rapidly increasing volume of samples needing review. We are equally excited about the global expansion of our engineering team in Bombay, India."
Crosscope Dx software provides end-to-end digital pathology and advanced, integrated, flexible workflow features in an open and stable architecture.
The acquisition includes a highly talented team with experience in AI, pathology, and medical software development that will join the Clarapath organization. Dr. Jayendra Shinde, co-founder and CEO of Crosscope added, "We are looking forward to what this combination represents as a new era for pathology, building a true fully-automated, digital, anatomic pathology laboratory solution."
Crosscope is a digital pathology firm that has a turnkey imaging solution with workflow tools, slide management, and artificial intelligence (AI) and machine learning (ML) tech to help pathologists make quicker, more informed decisions.
The acquisition combines Clarapath’s SectionStar, a fully automated, all-in-one tissue sectioning and transfer system with Crosscope’s workflow and computational pathology tools. The combined technologies aim to enable faster, more cost effective, and higher quality care delivery.
"Clarapath is thrilled to welcome Crosscope to the Clarapath team. We believe that the combination of SectionStar's exceptional automated robotics with Crosscope's advanced workflow and computational pathology tools provide an end-to-end platform for more patient-centric care in human and animal health," Eric Feinstein, CEO of Clarapath told the press. "Our combined offering will solve some of the most pressing issues in the lab such as labor shortages, quality control challenges, and the rapidly increasing volume of samples needing review. We are equally excited about the global expansion of our engineering team in Bombay, India."
Crosscope Dx software provides end-to-end digital pathology and advanced, integrated, flexible workflow features in an open and stable architecture.
The acquisition includes a highly talented team with experience in AI, pathology, and medical software development that will join the Clarapath organization. Dr. Jayendra Shinde, co-founder and CEO of Crosscope added, "We are looking forward to what this combination represents as a new era for pathology, building a true fully-automated, digital, anatomic pathology laboratory solution."